Oncology Drug Reference Sheet: Alpelisib
Kristine B. LeFebvre DNP, RN, NPD-BC, AOCN®
Voice
Description
When used in combination with fulvestrant, alpelisib (Piqray®) produced complete or partial responses in 29% of patients with PIK3CA-altered, estrogen receptor-positive advanced breast cancer in clinical trials. The U.S. Food and Drug Administration (FDA) approved it for use in 2019.
ONS Drug Education
Short summaries of newly approved oncology-related therapies or drugs with new indications.
View All Drug Education